{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Parkinson%27s+Disease&page=20&q=levodopa", "query": { "q": "levodopa", "condition": "Parkinson's Disease", "page": 20 }, "page_size": 10 }, "pagination": { "page": 20, "page_size": 10, "total_count": 256, "total_pages": 26, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Parkinson%27s+Disease&page=21&q=levodopa&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Parkinson%27s+Disease&page=19&q=levodopa&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T00:36:15.129Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01770145", "title": "Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Parkinson's Disease", "Motor Symptoms", "Akinesia", "Hypomobility", "Delayed Levodopa Onset" ], "interventions": [ { "name": "APOKYN", "type": "DRUG" }, { "name": "L-dopa", "type": "DRUG" }, { "name": "Trimethobenzamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 127, "start_date": "2012-12", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2023-08-14", "last_synced_at": "2026-10-16T00:36:15.129Z", "location_count": 12, "location_summary": "Los Angeles, California • Reseda, California • Washington D.C., District of Columbia + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Reseda", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01770145" }, { "nct_id": "NCT06234995", "title": "Cortical Electrophysiology of Response Inhibition in Parkinson's Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Parkinson Disease" ], "interventions": [ { "name": "Levodopa", "type": "DRUG" }, { "name": "Clinical DBS Setting", "type": "DEVICE" }, { "name": "Sham DBS", "type": "DEVICE" }, { "name": "DBS Setting Maximizing Prefrontal Activation", "type": "DEVICE" }, { "name": "DBS Setting Minimizing Prefrontal Activation", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "45 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "45 Years to 75 Years" }, "enrollment_count": 80, "start_date": "2021-08-09", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-10-16T00:36:15.129Z", "location_count": 2, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06234995" }, { "nct_id": "NCT00040196", "title": "How the Loss of Dopamine and Dopamine-Restoring Medicines Affect Movement Performance", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Parkinson Disease" ], "interventions": [], "intervention_types": [], "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 133, "start_date": "2002-06-19", "completion_date": "2009-07-09", "has_results": false, "last_update_posted_date": "2017-07-02", "last_synced_at": "2026-10-16T00:36:15.129Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00040196" }, { "nct_id": "NCT01283594", "title": "Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing Off", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Parkinson's Disease" ], "interventions": [ { "name": "Tozadenant (SYN115) 60 mg BID", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Levodopa (L-dopa)", "type": "DRUG" }, { "name": "Tozadenant (SYN115) 120 mg BID", "type": "DRUG" }, { "name": "Tozadenant (SYN115) 180 mg BID", "type": "DRUG" }, { "name": "Tozadenant (SYN115) 240 mg BID", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biotie Therapies Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "30 Years to 80 Years" }, "enrollment_count": 420, "start_date": "2011-03", "completion_date": "2012-10", "has_results": false, "last_update_posted_date": "2019-01-17", "last_synced_at": "2026-10-16T00:36:15.129Z", "location_count": 40, "location_summary": "Birmingham, Alabama • La Jolla, California • Loma Linda, California + 37 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oxnard", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01283594" }, { "nct_id": "NCT00605683", "title": "MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Idiopathic Parkinson's Disease" ], "interventions": [ { "name": "Safinamide (as add-on therapy)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Newron Pharmaceuticals SPA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "30 Years to 80 Years" }, "enrollment_count": 679, "start_date": "2007-11", "completion_date": "2012-03", "has_results": false, "last_update_posted_date": "2013-10-29", "last_synced_at": "2026-10-16T00:36:15.129Z", "location_count": 31, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Oxnard, California + 27 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Oxnard", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Sunnyvale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00605683" }, { "nct_id": "NCT03670953", "title": "A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Parkinson's Disease (Disorder)" ], "interventions": [ { "name": "IR CD-LD", "type": "DRUG" }, { "name": "IPX203 ER CD-LD", "type": "DRUG" }, { "name": "Placebo Matching IPX203", "type": "OTHER" }, { "name": "Placebo Matching IR CD-LD", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Impax Laboratories, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 630, "start_date": "2018-11-06", "completion_date": "2021-06-15", "has_results": true, "last_update_posted_date": "2023-02-09", "last_synced_at": "2026-10-16T00:36:15.129Z", "location_count": 56, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 46 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03670953" }, { "nct_id": "NCT02610231", "title": "Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Idiopathic Parkinson's Disease" ], "interventions": [ { "name": "Istradefylline 20 mg or 40 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kyowa Kirin Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": null, "sex": "ALL", "summary": "30 Years and older" }, "enrollment_count": 239, "start_date": "2015-12", "completion_date": "2017-12-20", "has_results": true, "last_update_posted_date": "2024-04-25", "last_synced_at": "2026-10-16T00:36:15.129Z", "location_count": 23, "location_summary": "Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 20 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02610231" }, { "nct_id": "NCT03984305", "title": "Utilization of Target Ranges to Treat Parkinson's Disease With the PKG", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Parkinson Disease" ], "interventions": [ { "name": "Personal KinetiGraph® (PKG®) Watch", "type": "DEVICE" }, { "name": "Personal KinetiGraph® (PKG®) Report", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Global Kinetics Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "46 Years", "maximum_age": "83 Years", "sex": "ALL", "summary": "46 Years to 83 Years" }, "enrollment_count": 41, "start_date": "2019-10-15", "completion_date": "2020-10-16", "has_results": true, "last_update_posted_date": "2022-02-08", "last_synced_at": "2026-10-16T00:36:15.129Z", "location_count": 17, "location_summary": "Fayetteville, Arkansas • Little Rock, Arkansas • Menlo Park, California + 14 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Menlo Park", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03984305" }, { "nct_id": "NCT00559871", "title": "Safety and Efficacy Study of Fipamezole in Treatment of Motor Dysfunctions in Parkinson's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Parkinson's Disease" ], "interventions": [ { "name": "fipamezole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Juvantia Pharma Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": null, "sex": "ALL", "summary": "30 Years and older" }, "enrollment_count": 180, "start_date": "2007-10", "completion_date": "2009-05", "has_results": false, "last_update_posted_date": "2009-06-03", "last_synced_at": "2026-10-16T00:36:15.129Z", "location_count": 29, "location_summary": "Birmingham, Alabama • Northport, Alabama • Tucson, Arizona + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Northport", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00559871" }, { "nct_id": "NCT07174310", "title": "A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Parkinson's Disease" ], "interventions": [ { "name": "Prasinezumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "50 Years to 85 Years" }, "enrollment_count": 900, "start_date": "2025-11-24", "completion_date": "2031-06-30", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-16T00:36:15.129Z", "location_count": 53, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Fullerton, California + 47 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07174310" } ] }